Blood Glucose Management/Probiotics Premix/ZC-SUGII/ Clinical Probiotic Strains
Shelf life: 24 months
Storage conditions: Stored at -18℃ or lower
Functional Strains
Bifidobacterium animalis subsp. lactis F1-7
Bifidobacterium animalis subsp. lactis BA-C9
Lactiplantibacillus plantarum YZX21
Lactiplantibacillus plantarum F3-2
Lactiplantibacillus plantarum H-87
Lacticaseibacillus paracasei G15
Main Functions
Lower blood glucose
Reduce body weight
Adjuvant therapy
1 Clinical Study · 6 Invention Patents · 17 Literature Studies
Clinical Registration Number: ChiCTR2400089551—A Randomized, Double-Blind, Placebo-Controlled Feeding Trial of Compound Lactic Acid Bacteria Powder for Improving Blood Glucose, Blood Lipids, and Body Mass Index in Patients with Type 2 Diabetes.
√ Achieved HbA1c <7.0 % within 90 days.
√ Improved insulin resistance, with a significant reduction in HOMA-IR.
√ Average weight reduction of 3.66 kg, with an average BMI decrease of 1.41.
Invention Patent: ZL202110019976.3 - A method for preparing and applying a combination of Bifidobacterium animalis subsp. lactis F1-7 and krill oil to improve atherosclerosis inflammation.
Tertiary Hospital · Clinical Evidence-Based Medicine
A Randomized, Double-Blind, Placebo-Controlled Feeding Trial of SugaRite ™ Premix Probiotics Powder for Improving Blood Glucose, Blood Lipids, and Body Mass Index in Patients with Type 2 Diabetes.
Research Institution: The Second Affiliated Hospital of Zhejiang University School of Medicine (a Grade III, Level A general hospital)
Total Sample Size: 60 patients with Type 2 Diabetes
Intervention Duration: 90 consecutive days of trial consumption
Primary Efficacy Endpoints: HbA1c, blood glucose, pancreatic islet function, insulin and C-peptide, blood lipid profile, body weight and BMI, etc.
Intervention Protocol: 2g, twice daily
Clinical Data 1: HbA1c reduced to below 7.0%, with a reduction of 0.73% and an attainment rate exceeding 80%.
Trial Notes: In the test group, the HbA1c attainment rate (<7.0%) reached 80.95%, with a significant absolute reduction of 0.73% (from a baseline of 7.14%). This reduction was 2.2 times greater than that observed in the control group, and the difference was statistically significant (P=0.0260).
This indicates that SugaRite ™ can effectively control HbA1c levels and may help prevent complications.
Clinical Data 2: Improved insulin resistance and restored insulin sensitivity.
Trial Notes: While achieving blood glucose control, the required levels of insulin and C-peptide in the test group were significantly lower than those in the control group. This difference became particularly pronounced after 60 days of trial consumption.Coupled with the significant reduction in HOMA-IR (Homeostatic Model Assessment for Insulin Resistance), these findings collectively indicate that SugaRite ™ effectively enhances the body's insulin sensitivity and can help ameliorate insulin resistance.
Clinical Data 3: Significant reductions in body weight and BMI, contributing to weight management.
Trial Notes: The test group showed a significant reduction in body weight by 3.66 kg from baseline (from 72.55 kg to 68.77 kg), and a reduction in BMI by 1.41 (from 26.47 to 25.06).This improvement was nearly twice that observed in the control group, with the difference reaching statistical significance. It demonstrates that SugaRite ™ can promote weight loss and improvement in BMI. Body Mass Index (BMI) and Body Weight: Weight reduction itself is one of the most effective methods for improving insulin resistance.
Clinical Report
SugaRite ™ Premix Probiotics powder can regulate blood glucose, lower HbA1c, ameliorate insulin resistance, restore insulin sensitivity, and support weight management.